EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy.
about
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerDNA damage in blood lymphocytes in patients after (177)Lu peptide receptor radionuclide therapy.Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.Calculation of Blood Dose in Patients Treated With 131I Using MIRD, Imaging, and Blood Sampling Methods.Estimating (131)I biokinetics and radiation doses to the red marrow and whole body in thyroid cancer patients: probe detection versus image quantification.Targeted radionuclide therapy.A novel planar image-based method for bone marrow dosimetry in (177)Lu-DOTATATE treatment correlates with haematological toxicityPediatric papillary thyroid cancer: current management challengesThe use of molecular imaging of gene expression by radiotracers in gene therapy.Differentiated thyroid cancer-personalized therapies to prevent overtreatment.Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology.Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients.Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of precPeptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force.Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine.The "reset button" revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients.Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level.Comparison of different dosimetric methods for red marrow absorbed dose calculation in thyroid cancer therapy.Radioactive (131)Iodine Body Burden and Blood Dose Estimates in Treatment for Differentiated Thyroid Cancer by External Probe Counting.Combining radioiodine and external beam radiation therapy: the potential of integrated treatment planning for differentiated thyroid cancer.Radioactive 131Iodine Body Burden and Blood Dose Estimates in Treatment for Differentiated Thyroid Cancer by External Probe Counting.Evaluation of the dosimetry approaches in ablation treatment of thyroid cancer.Correlation of the absorbed dose to the blood and DNA damage in leukocytes after internal ex-vivo irradiation of blood samples with Ra-224
P2860
Q26829349-B1EF66E8-F534-48C5-B190-2EC779236DB4Q30367068-97C9810A-BB89-4783-A557-635B794387BDQ36011116-01714944-C197-46D0-8FA1-9D99467456D6Q36516035-B2040F4C-B68F-4BE9-886D-03068287089FQ36822937-2EB6F63C-6E40-4065-8885-B78CDB6989EAQ37079244-38F8887E-BE7E-4C1C-B383-6D58009AC428Q37148148-1FA996E6-EA42-4DD7-A128-730160052568Q37273187-458C5694-157A-4B18-A35F-E64924B92881Q37551856-1433046F-CFF7-495D-9A01-CF33CFEA3F47Q37884052-761C654B-5E5F-49A7-911F-8FEA9C5EB09CQ38224994-D1534726-2D3F-439D-90BB-9A759667F299Q38571991-DBE0A6D4-6649-48E1-ABDA-9F758D06170EQ38879184-8D29996D-5DF7-458B-9138-D23B9ADABE0EQ39313472-85A002ED-E5A3-4ABA-9206-BA304483BAA0Q42345704-9A55862B-BFDF-4558-BFA5-4DE98CDB00FDQ47105571-D34EDFA7-316B-474F-9C88-ED90D273FE0FQ48139391-F5A20C97-47FE-403C-83A4-AB2867090F94Q48225241-1B3471C7-5266-43BA-9720-F9600D8A1386Q48699422-EE740CC2-5C02-49FB-B2AA-11C01D898B04Q50536307-EC39B2F2-C83E-42A3-9739-40C2E2434E7FQ51800697-3040F77E-DB1A-40C1-BFD4-BC85448FDA8FQ53987356-999F2893-E114-4BD8-B7A6-88E82499B618Q54612394-333C10E8-AEB3-4138-9453-A7D6457F5621Q55603732-5A12FE29-FC30-4710-8948-192A43F21EECQ58799320-549F8A3D-EDAF-4B5F-874B-9003BA9F4401
P2860
EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
EANM Dosimetry Committee serie ...... tiated thyroid cancer therapy.
@en
EANM Dosimetry Committee serie ...... tiated thyroid cancer therapy.
@nl
type
label
EANM Dosimetry Committee serie ...... tiated thyroid cancer therapy.
@en
EANM Dosimetry Committee serie ...... tiated thyroid cancer therapy.
@nl
prefLabel
EANM Dosimetry Committee serie ...... tiated thyroid cancer therapy.
@en
EANM Dosimetry Committee serie ...... tiated thyroid cancer therapy.
@nl
P2093
P1476
EANM Dosimetry Committee serie ...... tiated thyroid cancer therapy.
@en
P2093
Carlo Chiesa
Cecilia Hindorf
EANM Dosimetry Committee
Glenn Flux
Heribert Hänscheid
Markus Luster
Michael Lassmann
P2888
P304
P356
10.1007/S00259-008-0761-X
P577
2008-07-01T00:00:00Z